A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer

被引：1
|
作者：
El-Rayes, B. F. [1 ]
Hammad, N. [1 ]
Philip, P. A. [1 ]
Shields, A. F. [1 ]
Heilbrun, L. K. [1 ]
机构：
[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15608
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I/II trial of triplet regimen with docetaxel, oxaliplatin and capecitabine in advanced gastric and gastroesophageal cancers
    Eswaran, Prasad
    Kannan, Kalaichelvi
    Narasimhan, Srinivasan Lakshmi
    Kumar, Balaji Suresh
    Mavalavan, Dural
    [J]. CLINICAL CANCER INVESTIGATION JOURNAL, 2015, 4 (04): : 504 - 510
  • [32] Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
    Richards, Donald
    Kocs, Darren M.
    Spira, Alexander I.
    McCollum, A. David
    Diab, Sami
    Hecker, Lanny I.
    Cohn, Allen
    Zhan, Feng
    Asmar, Lina
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2823 - 2831
  • [33] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Arthur Lui
    Karen Mulder
    Christine Brezden-Masley
    Michael Vickers
    Jose Monzon
    Hagen Kennecke
    Rakesh Goel
    Larissa Vos
    Sunita Ghosh
    Horia Marginean
    Anthony Fields
    Jean Maroun
    Jennifer Spratlin
    [J]. Investigational New Drugs, 2018, 36 : 674 - 682
  • [34] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma
    Ilson, D.
    Janjigian, Y. Y.
    Shah, M. A.
    Tang, L. H.
    Kelsen, D. P.
    Campbell, J.
    Fuqua, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [35] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur
    Mulder, Karen
    Brezden-Masley, Christine
    Vickers, Michael
    Monzon, Jose
    Kennecke, Hagen
    Goel, Rakesh
    Vos, Larissa
    Ghosh, Sunita
    Marginean, Horia
    Fields, Anthony
    Maroun, Jean
    Spratlin, Jennifer
    [J]. INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 674 - 682
  • [36] A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer
    Balazs Halmos
    Yuxia Jia
    Joseph A. Bokar
    Pingfu Fu
    David J. Adelstein
    Rosalyn Juergens
    Mary Beth Rodal
    Afshin Dowlati
    [J]. Investigational New Drugs, 2013, 31 : 1244 - 1250
  • [37] A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer
    Halmos, Balazs
    Jia, Yuxia
    Bokar, Joseph A.
    Fu, Pingfu
    Adelstein, David J.
    Juergens, Rosalyn
    Rodal, Mary Beth
    Dowlati, Afshin
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1244 - 1250
  • [38] A single-arm, phase II feasibility study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
    Ryu, M.
    Choi, Y.
    Kim, B.
    Park, Y.
    Kim, H.
    Jung, H.
    Lee, G.
    Kim, K.
    Yook, J.
    Kang, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [39] Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
    Rosenberg, Ari Joseph
    Rademaker, Alfred
    Hochster, Howard S.
    Ryan, Theresa
    Hensing, Thomas
    Shankaran, Veena
    Baddi, Lisa
    Mahalingam, Devalingam
    Mulcahy, Mary F.
    Benson, Al B., III
    [J]. ONCOLOGIST, 2019, 24 (08): : 1039 - +
  • [40] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345